½ÃÀ庸°í¼­
»óǰÄÚµå
1404686

¹Ì±¹ÀÇ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

U.S. Home Infusion Therapy Market Size, Share & Trends Analysis Report By Product (Infusion Pumps, Needleless Connectors), By Application (Anti-Infective, Endocrinology), And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 116 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¹Ì±¹ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 318¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 7.7%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ¾Ï, ¸é¿ª °áÇÌ, Å©·Ðº´, °¨¿°, Å»¼ö, ¿µ¾ç ºÎÁ·, ´Ù¹ß¼º °æÈ­Áõ, ¸Þ½º²¨¿ò, ±¸Åä¿Í °°Àº Áúº´ÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÔ¿ø ±â°£ ´ÜÃà¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ³ëÀÎ Àα¸ÀÇ ¸¸¼º Áúȯ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¿ø³»°¨¿°(HAI)ÀÇ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¹Ì±¹ ÀçÅà ÁÖÀÔ ¿ä¹ý »ê¾÷ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ¸Å³â ¾à 170¸¸ ¸íÀÇ ÀÔ¿ø ȯÀÚ°¡ ÀÇ·á ÈÄõ¼º °¨¿°(HCAI)¿¡ °É¸®°í ¾à 98,000¸í(ȯÀÚ 17¸í Áß 1¸í)ÀÌ ÀÌ °¨¿°À¸·Î ÀÎÇØ »ç¸ÁÇÕ´Ï´Ù. ÀÌ¿¡ µû¶ó ÀçÅà ÁÖÀÔ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀçÅà ÁÖÀÔ ¿ä¹ý¿¡¼­ ÀÇ·á±â±â ¹× ÁÖÀÔ ÆßÇÁ¿Í ÇÔ²² ÀüÀÚ ÀÇ·á ±â·ÏÀ» µµÀÔÇÏ´Â µî ±â¼ú Çõ½ÅÀÌ Áõ°¡Çϰí ÀÖ´Â Ãß¼¼ÀÔ´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·ÏÀº ÀÇ·á ±â·ÏÀ» ÀúÀå, °Ë»ö ¹× ¼öÁ¤ÇÒ ¼ö ÀÖ¾î ÀÇ·á Àü¹®°¡¿Í ȯÀÚ°¡ ƯÁ¤ ÁúȯÀÇ °³¼±À» ½±°Ô ÃßÀûÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

ÀÔ¿ø¿¡ ºñÇØ ºñ¿ë È¿À²¼ºÀÌ ³ô±â ¶§¹®¿¡ ÀçÅà ÀǷḦ ¼±È£Çϴ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¾÷°è ¾÷üµéÀÌ º¸´Ù Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇÒ ¼ö ÀÖ´Â ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ÈÀü¼ºÀÌ ³ôÀº Á¦Ç°ÀÇ µµÀÔÀº ±Ã±ØÀûÀ¸·Î ¹Ì±¹ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COVID-19ÀÇ ÃâÇöÀ¸·Î Baxter, BD, ICU Medical, Option Care Health, Inc. ¿Í °°Àº ÁÖ¿ä ±â¾÷µéÀÌ 2020³â°ú 2021³â¿¡ ÀçÅà ÁÖÀÔ Á¦Ç° ¹× ¼­ºñ½º ¸ÅÃâ Áõ°¡¸¦ º¸°íÇϸ鼭 ±¹³» ÀçÅà ÁÖÀÔ ½ÃÀåÀÌ È°¼ºÈ­µÇ¾ú½À´Ï´Ù. ÀÌ ³ª¶óÀÇ ¸¹Àº ÀÇ·á ½Ã¼³ÀÌ º´¿ø ¹× ±âŸ ÀÇ·á ½Ã¼³¿¡¼­ ȯÀÚÀÇ ÀÔ¿ø ºÎ´ãÀ» ÁÙÀ̱â À§ÇØ °¡Á¤ ÁÖÀÔ ¼­ºñ½º¸¦ ¿µ±¸ÀûÀ¸·Î ¼±ÅÃÇÒ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ Ãß¼¼´Â ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ÁÖÀÔ ÆßÇÁ ºÎ¹®Àº ÇÊ¿äÇÑ ¾çÀÇ ¿µ¾çÁ¦, ¾àǰ ¹× ±âŸ ÇÊ¿äÇÑ ÁÖÀÔÀ» °ø±ÞÇÏ´Â µ¥ »ç¿ëµÇ¸ç, È¿À²¼ºÀÌ ³ô¾Æ ´Ù¸¥ ºÎ¹®¿¡ ºñÇØ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
  • ´Ïµé¸®½º Ä¿³ØÅÍ ºÎ¹®Àº ¼¼±Õ ¿À¿° À§ÇèÀÌ Àû°í ¹Ù´Ã¿¡ Âñ¸®Áö ¾Ê´Â µî ´Ù¾çÇÑ ÀåÁ¡À¸·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Ç×°¨¿°Á¦ ºÎ¹®Àº 2023³â ÀçÅà ÀÇ·á¿¡¼­ Ç×Áø±ÕÁ¦, Ç×»ýÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦·Î ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¸é¼­ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ³»ºÐºñ ºÐ¾ß´Â °©»ó¼±, ´ç´¢º´ µî ³»ºÐºñ°è °ü·Ã ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå : ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2018-2030³â

  • Á¦Ç° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • ¹Ì±¹ÀÇ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå, Á¦Ç°º°, 2023-2030³â
  • 2023³â¿¡¼­ 2030³â ½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®

Á¦4Àå ¹Ì±¹ÀÇ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå : ¿ëµµº° ºÎ¹® ºÐ¼®, 2018-2030³â

  • ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • ¹Ì±¹ÀÇ ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå, ¿ëµµº°, 2023-2030³â
  • 2023-2030³â ½ÃÀå ±Ô¸ð, ¿¹Ãø, µ¿Ç⠺м®

Á¦5Àå ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå : ±¹°¡º° ½ÃÀå ºÐ¼®, Á¦Ç°º°, 2018-2030³â

  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2023-2030³â
  • ¹Ì±¹

Á¦6Àå ÀçÅà ÁÖÀÔ ¿ä¹ý ½ÃÀå - °æÀï ºÐ¼®

  • Competitive Dashboard Analysis-Impact Analysis
    • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù(ÁÖ¿ä À̳뺣ÀÌÅÍ, ½ÃÀå ¸®´õ, ½ÅÈï ±â¾÷)
    • ÁÖ¿ä À̳뺣ÀÌÅÍ ¸®½ºÆ®
    • ½ÃÀå ¸®´õ ¸®½ºÆ®
    • ½ÅÈï ±â¾÷ ¸®½ºÆ®
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®(¸ÅÃâ, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ¼­ºñ½º °¡´ÉÇÑ »ê¾÷, ÁÖ¿ä Á¦ÈÞ)
    • ¸ÅÃ⺰
  • Strategy Framework
  • ±â¾÷ °³¿ä
    • B. Braun Melsungen AG
    • Baxter
    • Caesarea Medical Electronics
    • CareFusion Corporation
    • Fresenius Kabi AG
    • ICU Medical, Inc.
    • JMS Co., Ltd.
    • Smiths Medical
    • Terumo Corporation
    • Coram LLC
    • Option Care Enterprises, Inc.
    • BioScrip, Inc.
    • BriovaRx Infusion Services
    • Paragon Healthcare, Inc.
ksm 24.01.18

U.S. Home Infusion Therapy Market Growth & Trends:

The U.S. home infusion therapy market size is expected to reach USD 31.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 7.7% from 2024 to 2030. The growing geriatric population and increasing prevalence of disorders, such as cancer, immune deficiencies, Crohn's disease, infections, dehydration, nutritional deficiencies, multiple sclerosis, nausea, and vomiting are majorly driving the market's growth. The increasing need for reduced hospital stays and the rising prevalence of chronic disorders in the geriatric population are driving the growth.

Growing cases of Hospital Acquired Infections (HAI) is another major factor driving the growth of the U.S. home infusion therapy industry over the forecast period. According to the U.S. Centers for Disease Control and Prevention, approximately 1.7 million admitted patients are affected annually by Healthcare Acquired infections (HCAIs) and around 98, 000 patients (1 in 17 patients) die due to the same. Due to this, the demand for home infusion therapy is increasing substantially.

Increasing innovations in home infusion therapy such as the incorporation of electronic healthcare records along with medical devices and infusion pumps are trending. It allows storage, retrieval, and alteration of medical records, making it easier for healthcare professionals and patients to track the improvements in a particular disorder.

Increasing patients' preference for home healthcare since it is cost-efficient in comparison with hospital stays is an opportunity for the industry players to launch more innovative products. Also, the introduction of safety products will ultimately help the growth of the U.S. home infusion therapy market. The advent of COVID-19 boosted the home infusion market in the country as many key players like Baxter, BD, ICU Medical, and Option Care Health, Inc reported revenue increases for their home infusion products and services in 2020 and 2021. This trend is expected to further boost the market as numerous healthcare settings in the country are expected to permanently opt for home infusion services to decrease patient admission burden in hospitals and other healthcare facilities

U.S. Home Infusion Therapy Market Report Highlights:

  • The infusion pumps segment held the largest revenue share compared to others due to the increasing use and efficiency in delivering required quantities of nutrition, medications, and other essential fluids
  • The needleless connectors segment is expected to witness the fastest growth owing to various benefits, such as less risk of bacterial contamination and higher protection against needle stick injuries
  • The anti-infective segment held the maximum revenue share in 2023 owing to its extensive use as an antifungal, antibiotic, and antiviral agent at home care
  • Endocrinology is predicted to be the fastest-growing segment owing to the growing number of conditions associated with the endocrine system, such as thyroid and diabetes

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective 1
    • 1.8.2 Objective 2
    • 1.8.3 Objective 3
    • 1.8.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Penetration & Growth Prospect Mapping
  • 2.3 Market Dynamics
    • 2.3.1 Market driver analysis
      • 2.3.1.1 Increasing geriatric population
      • 2.3.1.2 Rising prevalence of chronic disorders
      • 2.3.1.3 Rapid technological advancements
      • 2.3.1.4 Growing incidence of hospital-acquired infections
      • 2.3.1.5 Home healthcare as a cost-effective alternative
    • 2.3.2 Market restrain analysis
      • 2.3.2.1 Presence of complicated reimbursement framework and reimbursement cuts
    • 2.3.3 Impact Of The 21st Century Cures Act And Projections For The Impact Of The Bipartisan Budget Act Of 2018.
    • 2.3.4 Trends For Home Infusion For Medicare Part B And Medicare Part D
  • 2.4 U.S. Home Infusion Therapy: Market Analysis Tools
    • 2.4.1 Industry analysis - Porter's
    • 2.4.2 PESTLE analysis
  • 2.5 U.S Home Infusion Therapy- Company Market Share Analysis 2023
  • 2.6 Major Deals & Strategic Alliances Analysis
  • 2.7 Procedure cost analysis/breakdown
  • 2.8 Technology Timeline
  • 2.9 Regulatory Framework
  • 2.10 Reimbursement framework

Chapter 3 U.S Home Infusion Therapy Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 3.1 Product Market Share Analysis, 2023 & 2030
  • 3.2 U.S. Home Infusion Therapy Market, by Product, 2023 to 2030
  • 3.3 Market Size & Forecasts and Trend Analyses, 2023 to 2030
    • 3.3.1 Infusion pumps
      • 3.3.1.1 Infusion Pumps Market, 2018 - 2030 (USD Million)
      • 3.3.1.2 Elastomeric Market, 2018 - 2030 (USD Million)
      • 3.3.1.3 Electromechanical Market, 2018 - 2030 (USD Million)
      • 3.3.1.4 Gravity Market, 2018 - 2030 (USD Million)
      • 3.3.1.5 Others Market, 2018 - 2030 (USD Million)
    • 3.3.2 Intravenous sets
    • 3.3.3 Intravenous Sets Market, 2018 - 2030 (USD Million)
    • 3.3.4 Gravity Sets Market, 2018 - 2030 (USD Million)
    • 3.3.5 Dedicated Sets Market, 2018 - 2030 (USD Million)
    • 3.3.6 IV Cannulas
      • 3.3.6.1 IV Cannulas Market, 2018 - 2030 (Usd Million)
    • 3.3.7 Needleless Connectors
      • 3.3.7.1 Needleless Connectors Market, 2018 - 2030 (USD Million)

Chapter 4 U.S. Home Infusion Therapy Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 4.1 Application Market Share Analysis, 2023 & 2030
  • 4.2 U.S. Home Infusion Therapy Market, by Application, 2023 to 2030
  • 4.3 Market Size & Forecasts and Trend Analyses, 2023 to 2030
    • 4.3.1 Anti-Infective
      • 4.3.1.1 Anti-infective market, 2018 - 2030 (USD Million)
    • 4.3.2 endocrinology
      • 4.3.2.1 ENDOCRINOLOGY MARKET, 2018 - 2030 (USD Million)
      • 4.3.2.2 Diabetes market, 2018 - 2030 (USD Million)
      • 4.3.2.3 Others market, 2018 - 2030 (USD Million)
    • 4.3.3 Hydration therapy
      • 4.3.3.1 hydration therapy market, 2018 - 2030 (USD Million)
      • 4.3.3.2 Athletes market, 2018 - 2030 (USD Million)
      • 4.3.3.3 Others market, 2018 - 2030 (USD Million)
    • 4.3.4 Chemotherapy
      • 4.3.4.1 CHEMOTHERAPY MARKET, 2018 - 2030 (USD Million)
    • 4.3.5 Enteral nutrition
      • 4.3.5.1 ENTERAL NUTRITION market, 2018 - 2030 (USD Million)
    • 4.3.6 Parenteral nutrition
      • 4.3.6.1 PARENTERAL NUTRITION market, 2018 - 2030 (USD Million)
    • 4.3.7 Specialty pharmaceuticals
      • 4.3.7.1 SPECIALTY PHARMACEUTICALS MARKET, 2018 - 2030 (USD Million)
    • 4.3.8 Others
      • 4.3.8.1 Others market, 2018 - 2030 (USD Million)

Chapter 5 Home Infusion Therapy Market: Country Market Analysis, By Product, 2018 - 2030 (USD Million)

  • 5.1 Market Size, & Forecasts and Trend Analysis, 2023 to 2030
  • 5.2 U.S.
    • 5.2.1 U.S. Home Infusion Therapy market, by product, 2018 - 2030 (USD Million)
    • 5.2.2 U.S. Home Infusion Therapy market, by Appliction, 2018 - 2030 (USD Million)

Chapter 6 Home Infusion Therapy Market - Competitive Analysis

  • 6.1 Competitive Dashboard Analysis - Impact Analysis
    • 6.1.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
    • 6.2.1 List of key innovators
    • 6.2.2 List of market leader
    • 6.2.3 List of emerging players
  • 6.3 Company market position analysis (Revenue, product portfolio, key serviceable industries, key alliances)
    • 6.3.1 By Revenue
  • 6.4 Strategy Framework
  • 6.5 Company Profiles
    • 6.5.1 B. Braun Melsungen AG
      • 6.5.1.1 Company overview
      • 6.5.1.2 Financial performance
      • 6.5.1.3 Product benchmarking
      • 6.5.1.4 Strategic initiatives
    • 6.5.2 Baxter
      • 6.5.2.1 Company overview
      • 6.5.2.2 Financial performance
      • 6.5.2.3 Product benchmarking
      • 6.5.2.4 Strategic initiatives
    • 6.5.3 Caesarea Medical Electronics
      • 6.5.3.1 Company overview
      • 6.5.3.2 Product benchmarking
      • 6.5.3.3 Strategic initiatives
    • 6.5.4 CareFusion Corporation
      • 6.5.4.1 Company overview
      • 6.5.4.2 Financial performance
      • 6.5.4.3 Product benchmarking
      • 6.5.4.4 Strategic initiatives
    • 6.5.5 Fresenius Kabi AG
      • 6.5.5.1 Company overview
      • 6.5.5.2 Financial performance
      • 6.5.5.3 Product benchmarking
      • 6.5.5.4 Strategic initiatives
    • 6.5.6 ICU Medical, Inc.
      • 6.5.6.1 Company overview
      • 6.5.6.2 Financial performance
      • 6.5.6.3 Product benchmarking
      • 6.5.6.4 Strategic initiatives
    • 6.5.7 JMS Co., Ltd.
      • 6.5.7.1 Company overview
      • 6.5.7.2 Financial performance
      • 6.5.7.3 Product benchmarking
    • 6.5.8 Smiths Medical
      • 6.5.8.1 Company overview
      • 6.5.8.2 Financial performance
      • 6.5.8.3 Product benchmarking
      • 6.5.8.4 Strategic initiatives
    • 6.5.9 Terumo Corporation
      • 6.5.9.1 Company overview
      • 6.5.9.2 Financial performance
      • 6.5.9.3 Product benchmarking
      • 6.5.9.4 Strategic initiatives
    • 6.5.10 Coram LLC
      • 6.5.10.1 Company overview
      • 6.5.10.2 Product benchmarking
    • 6.5.11 Option Care Enterprises, Inc.
      • 6.5.11.1 Company overview
      • 6.5.11.2 Financial performance
      • 6.5.11.3 Product benchmarking
      • 6.5.11.4 Strategic initiatives
    • 6.5.12 BioScrip, Inc.
      • 6.5.12.1 Company overview
      • 6.5.12.2 Financial performance
      • 6.5.12.3 Product benchmarking
      • 6.5.12.4 Strategic initiatives
    • 6.5.13 BriovaRx Infusion Services
      • 6.5.13.1 Company overview
      • 6.5.13.2 Financial performance
      • 6.5.13.3 Product benchmarking
      • 6.5.13.4 Strategic initiatives
    • 6.6.14 Paragon Healthcare, Inc.
      • 6.6.14.1 Company overview
      • 6.6.14.2 Financial performance
      • 6.6.14.3 Product benchmarking
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦